title: Hemostatic Changes During Extracorporeal Membrane Oxygenation: A Prospective Randomized Clinical Trial Comparing Three Different Extracorporeal Membrane Oxygenation Systems.
abstract: OBJECTIVE
  Extracorporeal membrane oxygenation is a rescue therapy for patients with severe lung failure. Major complications caused by extracorporeal membrane oxygenation are bleeding, thrombosis, and hemolysis. The aim of this study was to compare the impact of different extracorporeal membrane oxygenation systems on blood hemostasis in adults during veno-venous extracorporeal membrane oxygenation therapy.
  
  
  METHODS
  Single center prospective randomized study.
  
  
  METHODS
  University Hospital Regensburg, Germany.
  
  
  METHODS
  Adult patients with severe acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation therapy.
  
  
  METHODS
  None.
  
  
  RESULTS
  Three different extracorporeal membrane oxygenation systems: the Cardiohelp system (Maquet Cardiopulmonary AG), the Dideco ECC.O5 (Sorin Group), and the Deltastream system with Hilite 7000 LT + DP3 pumphead (Medos Medizintechnik AG) were compared. Therefore hemostasis, anticoagulation, hemolysis, and inflammatory parameters were monitored. Of the 54 patients included in the study, 18 patients each were randomly assigned to the three different extracorporeal membrane oxygenation systems. Exclusion criteria were acute renal failure, trauma, and surgery within 2 days. The median time on veno-venous extracorporeal membrane oxygenation support was 13.5 days (4-70 d). Median platelet count had dropped from 220.5 G/L before extracorporeal membrane oxygenation therapy to a minimum of 133 G/L by the last day of extracorporeal membrane oxygenation support. During the first 5 days of extracorporeal membrane oxygenation therapy, prothrombin fragment 1.2 (F1.2) (1.36-2.4 µM), thrombin-antithrombin complex (14.5-50 µg/L), and D-dimers (6.00-27.0 mg/L) increased, whereas fibrinogen values dropped from 5.8 to 4.1 g/L. The three different extracorporeal membrane oxygenation systems did not show any differences with regard to hemostasis, anticoagulation, hemolysis, and inflammatory parameters within the first 5 days of extracorporeal membrane oxygenation therapy.
  
  
  CONCLUSIONS
  Over time, miniaturized veno-venous extracorporeal membrane oxygenation therapy increasingly activates coagulation. The different types of membrane oxygenators and pumps did not significantly alter hemostasis.
authors.affiliation: 1Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany. 2Department of Cardiothoracic Surgery, University Medical Center Regensburg, Regensburg, Germany. 3Center for Clinical Studies, University Medical Center Regensburg, Regensburg, Germany. 4Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 5Department of Anesthesiology, University Medical Center Regensburg, Regensburg, Germany.
authors.forename: Maximilian V
authors.initials: MV
authors.lastname: Malfertheiner
authors.forename: Alois
authors.initials: A
authors.lastname: Philipp
authors.forename: Matthias
authors.initials: M
authors.lastname: Lubnow
authors.forename: Florian
authors.initials: F
authors.lastname: Zeman
authors.forename: Tone Bull
authors.initials: TB
authors.lastname: Enger
authors.forename: Thomas
authors.initials: T
authors.lastname: Bein
authors.forename: Dirk
authors.initials: D
authors.lastname: Lunz
authors.forename: Christof
authors.initials: C
authors.lastname: Schmid
authors.forename: Thomas
authors.initials: T
authors.lastname: Müller
authors.forename: Karla
authors.initials: K
authors.lastname: Lehle
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation / Q000502:physiology; D015199:Extracorporeal Membrane Oxygenation / Q000295:instrumentation*; D005260:Female; D005858:Germany; D006461:Hemolysis / Q000502:physiology*; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments; D011446:Prospective Studies; D011516:Prothrombin; D012128:Respiratory Distress Syndrome / Q000503:physiopathology / Q000628:therapy*; D012131:Respiratory Insufficiency / Q000628:therapy; D013927:Thrombosis
chemical_list: D000925:Anticoagulants; D010446:Peptide Fragments; C045879:prothrombin fragment 1.2; D011516:Prothrombin